Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Share-based Compensation for 4 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 16.11% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, up 19.43% year-over-year, with the annual reading at $28.7 million for FY2025, 19.43% up from the prior year.
  • Share-based Compensation for Q4 2025 was $5.6 million at Phathom Pharmaceuticals, down from $9.3 million in the prior quarter.
  • The five-year high for Share-based Compensation was $19.3 million in Q4 2023, with the low at $5.5 million in Q1 2025.
  • Average Share-based Compensation over 4 years is $7.3 million, with a median of $6.1 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 189.92% in 2023, then crashed 65.35% in 2024.
  • Over 4 years, Share-based Compensation stood at $6.7 million in 2022, then skyrocketed by 189.92% to $19.3 million in 2023, then plummeted by 65.35% to $6.7 million in 2024, then decreased by 16.11% to $5.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.6 million, $9.3 million, and $8.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.